Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (12): 1170-1173.doi: 10.35541/cjd.20210850

• Reviews • Previous Articles     Next Articles

Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas

Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei   

  1. Department of Dermatology, Peking University Third Hospital, Beijing 100191, China
  • Received:2021-11-24 Revised:2022-07-18 Online:2023-12-15 Published:2023-12-05
  • Contact: Zhang Chunlei
  • Supported by:
    National Natural Science Foundation of China (81972560); Beijing Natural Science Foundation (7202231); The Fund for Fostering Young Scholars of Peking University Health Science Center of China (BMU2020PYB023)

Abstract: 【Abstract】 With the advances in research on cutaneous T cell lymphomas (CTCL), some new strategies, such as traditional targeted drugs, immune checkpoint inhibitors, histone deacetylase inhibitors and allogeneic hematopoietic stem cell transplantation, have emerged and shown favorable efficacy and safety in clinical trials. This review summarizes recent research progress in non-chemotherapeutic drugs for relapsed/refractory cutaneous T-cell lymphomas.

Key words: Lymphoma, T-cell, cutaneous, Molecular targeted therapy, Immune checkpoint inhibitor, Allogeneic hematopoietic stem cell transplantation, CAR T-cell therapy